China CROs Step Out Into The World
This article was originally published in PharmAsia News
Executive Summary
Recent activities by China's leading contract research organizations - Wuxi Pharma's acquisition of U.S.-based AppTec laboratory services, joint ventures between Rundo and Japanese Cronova as well as Medicilon and U.S. firm MPI Research - signal that local Chinese corporations are ready to forge closer partnerships with overseas enterprises to boost their technology. In addition, such cooperation will help facilitate the partners entering each other's market. At present, no Chinese CRO has yet met international good laboratory practices standards owing to a lack of specialized talents to set up and manage GLP laboratories. Analysts say that local CROs must meet international technology standards and close the gap with large multinational CROs to enhance their competitiveness in a global market. (Click here for more)
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.